Gaucher

 

Epidemiology and Etiology:

·         cluster of autosomal recessive disorders

·         mutations in the GBA gene (1q21) encoding glucocerebrosidase (glucosylceramidase)

·         enzyme that normally cleaves the glucose residue from ceramide

·         Glucocerebrosides are continually formed from the catabolism of glycolipids derived mainly from the cell membranes of senescent leukocytes and erythrocytes

·         As a result, glucocerebroside accumulates principally in the phagocytic cells of the body but in some forms also in the central nervous system

·         most common lysosomal storage disorder

·         type I (chronic non-neuronopathic)

·         reduced but detectable levels of glucocerebrosidase activity

·         glucocerebrosides is limited to the mononuclear phagocytes throughout the body without involving the brain

·         principally in Jews of European stock

·         type II (acute neuronopathic)

·         virtually no detectable glucocerebrosidase activity

·         no predilection for jews

·         type III

·         intermediate form

·          

 

Common sites:

·         type I

·         spleen

·         bone marrow

·         type II

·         hepatosplenomegaly

·         progressive CNS involvement begins in infancy

·         type III

·         progressive CNS involvement begins in teens or twenties

 

Gross features:

·         splenomegaly (type I)

·         uniformly pale or mottled

·         lymphadenopathy (mild to moderate, generalized)

·         bone

·         pathologic fractures (type I)

 

Histologic features:

·         Distended phagocytic cells (Gaucher cells) in spleen, liver, bone marrow, lymph nodes, tonsils, thymus, Peyer’s patches

·         Crumpled tissue paper appearance of cytoplasm (not vacuolated)

 

Immunophenotype & Special Stains:

Marker:

Sensitivity:

Specificity:

PAS (intense) 

 

 

 

Molecular features:

·         GBA gene (1q21) mutations

·         more than 150 allelic mutations

·         N370S, 84GG, IVS2+1G>A, and L444P account for 90% of the mutant alleles in Ashkenazi Jewish individuals with type 1 GD and for 50%-60% of mutant alleles in non-Jewish individuals with type 1 GD

 

Other features:

·         Diagnosis by measurement of glucocerebrosidase activity in peripheral blood leukocytes or in extracts of cultured skin fibroblasts

·         Chitotriosidase, an enzyme synthesized by macrophages, is markedly elevated (reasonably specific)

·         EM:

·         Elongated, distended lysosomes containing stored lipid in stacks of bilayers

·         Pancytopenia or thrombocytopenia due to hypersplenism

·         Progressive CNS dysfunction (types II and III)

·         Convulsions

·         Progressive mental deterioration

·         Prognosis:

·         Type I

·         Longevity is shortened but not markedly

·         Type II

·         Death at an early age due to progressive CNS involvement

 

References:

·         Kumar V, Fausto N, Abbas A. Robbins & Cotran Pathologic Basis of Disease, Seventh Edition. 7th ed. Saunders; 2004:1552.